Ascentage Pharma Group International American Depository Shares (AAPG) vs Oric Pharmaceuticals (ORIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Oric Pharmaceuticals (ORIC) has outperformed Ascentage Pharma Group International American Depository Shares (AAPG) over the past year, losing 14.9% versus a loss of 61.6%. Ascentage Pharma Group International American Depository Shares is the larger company by market cap ($1.35 billion vs $1.24 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AAPG | ORIC |
|---|---|---|
| Share price | $14.46 | $11.99 |
| Market cap | $1.35B | $1.24B |
| 1-day change | -4.68% | -0.21% |
| YTD return | -43.06% | +46.82% |
| 1-year return | -61.57% | -14.94% |
| 5-year return | — | -26.00% |
| EPS (TTM) | $-2.26 | $-1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.58 | $14.68 |
| 52-week low | $14.46 | $7.23 |
| Distance from 52-week high | -62.52% | -18.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +225.93% | +78.81% |
| Average volume | 6.33K | 1.45M |
| Shares outstanding | 93.39M | 103.65M |
| Employees | 828 | 111 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORIC has outperformed AAPG by 46.6 percentage points over the past year.
About Ascentage Pharma Group International American Depository Shares
AAPG stock →Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Health Care · Biotechnology: Pharmaceutical Preparations · 828 employees
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees
AAPG vs ORIC FAQ
Which is bigger, Ascentage Pharma Group International American Depository Shares or Oric Pharmaceuticals?
Ascentage Pharma Group International American Depository Shares (AAPG) is larger, with a market capitalization of $1.35B compared with $1.24B for Oric Pharmaceuticals (ORIC).
Which stock has performed better over the past year, AAPG or ORIC?
ORIC returned -14.94% over the past 12 months, compared with -61.57% for AAPG (price return, excluding dividends). Past performance does not predict future results.
Are Ascentage Pharma Group International American Depository Shares and Oric Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.